Prevenar 13® Vaccine Will Be Available at Lowest Price for Humanitarian Emergencies
Pfizer to Donate Sales Proceeds to Organizations Supporting the Refugee Crisis
Pfizer Inc. (NYSE:PFE) announced today a major expansion of its humanitarian assistance program enabling broader access to its vaccine, Prevenar 13, in humanitarian emergency settings by offering its new multi-dose vial (MDV) at what will be the lowest prevailing global price, currently $3.10 per dose. In addition, given the acute need for aid on the ground, Pfizer will donate all sales proceeds for the first year of this program to humanitarian groups undertaking the difficult work of reaching vulnerable populations in emergency settings. Today’s announcement of a new and specific pricing tier for civil society organizations (CSOs) working in emergency settings builds on Pfizer’s longstanding support for humanitarian emergency relief around the world.
In the immediate term, Pfizer will meet humanitarian emergency needs through a short-term donation of the single-dose vial of Prevenar 13, which is available for expedited delivery.
Starting in 2017, refugees can receive the newest version of Prevenar 13, the MDV. This presentation is scheduled to be introduced early next year and contains four doses of Prevenar 13 in the same-sized vial that currently contains a single dose. This four-in-one vial is specially designed to address the unique conditions and challenges experienced in developing world settings and can help health workers in humanitarian emergencies. The MDV offers reduced cold storage and transportation requirements, helping to enable vaccination of children in humanitarian emergency situations more quickly. It has also been prequalified by the World Health Organization.
“Pfizer is proud of the significant impact that our Prevenar 13 vaccine and our partnerships with many humanitarian organizations have had on public health across the globe. Only by putting the needs of refugees at the center, can we all work collaboratively to help prevent disease in some of the world’s most vulnerable populations,” said Susan Silbermann, President and General Manager, Pfizer Vaccines. “Our new MDV presentation is an important vaccine technology, and in combination with our expanded humanitarian assistance program, will provide critical help in addressing the potential burden of pneumococcal disease in these populations that might otherwise go unreached. We are especially pleased to donate all proceeds from these sales to civil society organizations for the first year to support the significant additional needs these groups have on the ground.”
Pfizer Humanitarian Assistance Programs
Recognizing the critical need in settings requiring relief and emergency humanitarian assistance, Pfizer has a three-part approach which includes product donations, cash grants and other access solutions.
- Pfizer donations are focused on specific diseases and designed to address the needs of people in a coordinated manner. The Company works with a range of local and global partners, including governments, health care experts, and CSOs to address the most pressing unmet medical needs and determine the most effective way for a donation to meet the needs of affected communities.
- Pfizer supports a number of organizations working on providing relief and emergency humanitarian assistance to address refugee crises. The Pfizer Foundation provides cash grants to organizations working around the world to provide health care and other critical support to vulnerable populations.
- Pfizer works closely with governments and CSOs to help provide access to its vaccines and regularly engages in discussions with partners on potential new access approaches to reach as many people as possible in emergency humanitarian situations.
For more information on Pfizer’s Humanitarian Assistance Programs please visit http://www.pfizer.com/responsibility/global-health/relief-and-emergency-humanitarian-assistance.
About Prevenar 13®
Prevenar 13®*(pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]) was first approved in the European Union (EU) in December 2009 for use in infants and young children to help protect against invasive pneumococcal disease. Prevenar 13® is approved for such use in more than 150 countries worldwide, including the United States, Canada, Australia and Japan. Prevenar 13® is the most widely used pneumococcal conjugate vaccine in the world, and is included in the pediatric National Immunization Programs in 102 countries.i,ii It is approved in the United States, EU and other countries for use in infants, older children and adolescents aged 6 to 17 years.
*Trademark. Prevnar 13® is the trade name in the United States, Canada, and Taiwan.
U.S. IMPORTANT SAFETY INFORMATION
- Prevnar 13® should not be given to anyone with a history of severe allergic reaction to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine
- Children and adults with weakened immune systems (eg, HIV infection, leukemia) may have a reduced immune response
- A temporary pause of breathing following vaccination has been observed in some infants born prematurely
- The most commonly reported serious adverse events in infants and toddlers were bronchiolitis (an infection of the lungs) (0.9%), gastroenteritis (inflammation of the stomach and small intestine) (0.9%), and pneumonia (0.9%)
- In children 6 weeks through 17 years, the most common side effects were tenderness, redness, or swelling at the injection site, irritability, decreased appetite, decreased or increased sleep, and fever
- Only a healthcare provider can decide if Prevnar 13® is right for you or your child
For the full prescribing information for Prevnar 13®, please click here http://www.pfizer.com/products/product-detail/prevnar_13.
Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is as of November 11, 2016. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information regarding Prevnar 13/Prevenar 13, including its potential benefits and the expected timing of the introduction of the four-dose, multi-dose vial (MDV) presentation, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to meet the anticipated timing of introduction of the MDV presentation of Prevenar 13; uncertainties regarding the commercial impact of the MDV presentation of Prevenar 13; uncertainty regarding whether the anticipated benefits of the World Health Organization prequalification will be realized; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of Prevnar 13/Prevenar 13; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
i Data on file. Pfizer Inc, New York, NY. [Total Prevenar 13V Doses Through May 2016]
ii GlaxoSmithKline. GSK’s Synflorix™ receives CHMP positive opinion for major label extension. July 27, 2015. http://www.gsk.com/en-gb/media/press-releases/2015/gsk-s-synflorix-receives-chmp-positive-opinion-for-major-label-extension/. Accessed July 7, 2016.